drugset / Trial / NCT00222625
rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets
RandomizedParallel-groupSingle-blindTreatment
Summary
Evaluation of efficacy and safety of recombinant factor VIIa versus standard therapy in preventing early haematoma growth in spontaneous acute intracerebral haemorrhage in patients treated with oral anticoagulants or antiplatelets agents
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2006-09
Publications
- Eilertsen H, Menon CS, Law ZK, Chen C, Bath PM, Steiner T, Desborough MJ, Sandset EC, Sprigg N, Al-Shahi Salman R. Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD005951. doi: 10.1002/14651858.CD005951.pub5.
- Iorio A. Iatrogenic causes of an ICH: OAT therapy. Eur J Anaesthesiol Suppl. 2008;42:8-11. doi: 10.1017/S0265021507003171.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fresh Frozen Plasma | Protein / enzyme biologic | — | — |
| Subject | aPCC | Unknown | — | — |
| Subject | rFVIIa | Protein / enzyme biologic | — | — |
| Background | vit K | Unknown | — | — |